Fruquintinib for advanced colorectal cancer in minority populations
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a medication called fruquintinib (an oral pill) for people with advanced colorectal cancer that has not responded to prior treatments. It is specifically looking for participants who identify as Black or African American and/or Hispanic or Latino to help understand how the drug works in these groups.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have advanced colorectal cancer that has spread to other parts of the body, and it has been confirmed by a biopsy.
- You have already tried standard treatments, including certain chemotherapies and a biologic therapy like Avastin.
- You identify as Black or African American and/or Hispanic or Latino.
- You are in generally good health (able to do light chores or work) and weigh at least 88 pounds (40 kg).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called fruquintinib, given alone or with a chemotherapy infusion directly into your liver, for people whose colorectal cancer has spread to the liver and has stopped responding to standard treatments. It aims to find a new option for patients with limited cancer outside the liver.
This trial is testing a new combination of two oral cancer drugs (fruquintinib and S-1) in people with metastatic colorectal cancer who have already had at least one prior chemotherapy. The goal is to see if this combination helps shrink or slow the growth of tumors.
This trial studies fruquintinib combined with serplulimab (an immune therapy) for advanced colorectal cancer that has spread and is no longer responding to standard treatments. It may help by slowing the cancer’s growth and improving outcomes after the usual options have been tried.
This trial tests a combination of two drugs, fruquintinib and FOLFIRI chemotherapy, as a second treatment option for people with metastatic colorectal cancer. It is designed for patients who have already received one prior treatment containing oxaliplatin, fluoropyrimidine, and bevacizumab.
This trial tests whether adding TAS-102 to fruquintinib works better than fruquintinib alone for people with advanced colorectal cancer that has stopped responding to other treatments.
This trial tests whether combining fruquintinib (a pill) with low-level radio waves can help people whose metastatic colorectal cancer has stopped responding to or is intolerant of standard treatments. It’s for those who have tried certain chemotherapies and anti-VEGF therapy.
Hear when a new Colorectal cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.